Nektar Therapeutics (NASDAQ:NKTR) registered a 4.29% increase, still its new closing price is 20.06% up from the company’s 1 year high of 19.98.It posted 1.77% gains in previous 5 sessions and is now the subject of 0 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 4 buy or better ratings. The 8 stock analysts following this company have an average price target at $19.75, with individual PT in the $15.00-$25.00 range. The shares moved at $12.63, implying that brokerage firms see shares gaining about 3.87% in twelve months time.

Nektar Therapeutics (NKTR) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 2.93% rise year to date. A President & CEO at Nektar Therapeutics (NKTR) offloaded shares in a transaction closed on Tuesday January 17, 2017. ROBIN HOWARD W sold 87,500 shares in the company at $12.35 each and collected $1,080,001 in proceeds. ROBIN HOWARD W now owns 178,318 shares in the company after this transaction. A President & CEO in the company, ROBIN HOWARD W, disclosed a transaction on Wednesday December 07, 2016 that ended up generating $1,071,000 from the sale of 87,500 shares at $12.24 per share.

Nektar Therapeutics (NASDAQ:NKTR) Upcoming Results on Tap

Nektar Therapeutics will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.16 in that period. Sales during the quarter are predicted to arrive at $45.05 million.

Nektar Therapeutics (NKTR) Brokerage Update 

Nektar Therapeutics (NKTR) is in MKM Partners’s research list so their analyst rating change is noteworthy. These shares were downgraded to Neutral from Buy by MKM Partners, according to news reported on Thursday February 27, 2014.Another important research note was issued by ThinkEquity on Tuesday February 15, 2011.The firm downgraded NKTR to Hold from Buy. Over the last six months and over the last three months, the shares of Nektar Therapeutics (NKTR), have changed -26.48% and 1.85%, respectively.